What is the primary purpose of this 8-K filing?

This 8-K filing primarily serves to disclose material decisions made by Pfizer's Compensation Committee regarding executive and director compensation. This includes annual salaries, bonus awards, long-term incentive grants (stock options, restricted stock units, performance shares), and changes to severance agreements and director compensation structures.

How is executive compensation structured at Pfizer based on this filing?

Executive compensation is a mix of short-term and long-term incentives. Short-term compensation includes annual base salaries and cash bonuses tied to company and individual performance against financial and strategic objectives. Long-term compensation includes stock options, restricted stock units that vest over time, and performance shares where payout is contingent on achieving specific Total Shareholder Return (TSR) targets relative to industry peers over a multi-year period.

What changes were made to the executive severance agreements in the event of a change in control?

The amendment changed how outstanding performance-contingent share awards are valued and paid out if an executive is terminated without cause or resigns for good reason following a change in control. Previously, these awards were calculated based on the maximum potential number of shares. Under the amendment, they will now be based on the target number of shares, which is generally lower and thus potentially less lucrative for the executive in such a scenario.

How is the compensation for non-employee Directors changing?

The compensation for non-employee Directors is shifting from a fee-based structure (meeting fees, committee retainers) to a retainer-based model. Directors will receive an annual retainer and an award of Pfizer stock units upon joining or being re-elected. Additional retainers will be provided to committee chairs and the lead independent director. Meeting attendance below 80% will result in a pro-rated retainer.

PFE 8-K: Material Agreements

Summary

Pfizer Inc. (PFE) filed an 8-K on February 24, 2006, detailing executive compensation decisions made by its Compensation Committee on February 23, 2006. The report outlines approved annual base salaries, cash bonus awards for fiscal year 2005, and various long-term incentive grants for Named Executive Officers (NEOs). These include stock options, restricted stock units, and performance shares tied to future company performance relative to industry peers. The filing also discloses changes to executive severance agreements in the event of a change in control, shifting the payout basis from maximum to target shares for certain awards. Additionally, the report announces adjustments to the compensation structure for non-employee Directors, effective March 1, 2006. This transition moves away from meeting fees towards an annual retainer and stock unit awards, with additional retainers for committee chairs and the lead independent director. Investors should note that this filing provides details on compensation decisions impacting key leadership and governance, with further comprehensive compensation information expected in the upcoming 2006 Proxy Statement.

Key Highlights

1Pfizer's Compensation Committee approved annual base salaries, effective April 1, 2006, and awarded 2005 cash bonuses to Named Executive Officers (NEOs).
2The company awarded long-term incentive payouts for performance periods ending December 31, 2005, based on relative total shareholder return and earnings per share.
3Significant grants of stock options and restricted stock units (RSUs) were issued to NEOs in 2006, with options vesting over three years and RSUs vesting in three years.
4A new Executive Long-Term Incentive Program was adopted, featuring performance shares tied to Total Shareholder Return (TSR) relative to industry peers over a three-year period (2006-2008).
5Amendments to Executive Change-in-Control Severance Agreements were made, altering the payout calculation for outstanding performance-contingent share awards from maximum to target shares upon termination following a change in control.
6Compensation for non-employee Directors is being restructured, eliminating meeting fees and retainers in favor of a fixed annual retainer and stock unit awards, with additional retainers for committee chairs and the lead independent director.

PFIZER INC 8-K Report, Material Agreement (Feb 24, 2006)

Summary

Key Highlights

Frequently Asked Questions